PolyPid Ltd.
PYPDHealthcare|Biotechnology|IL
$6.14
+0.47 (+8.29%)
DCF Value
$0.12
Tangible Book / Share
$0.24
Cash / Share
$0.29
About
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
Stock Price
+61.6%(1Y)
1M
+25.3%
3M
+26.9%
6M
+40.2%
YTD
+41.5%
1Y
+64.2%
3Y
+46.9%
5Y
-97.5%
Pipeline Summary
7 total trials1
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
Completed: 6Terminated: 1
Key Facts
Market Cap$124.7M
Employees59
CEODikla Czaczkes Akselbrad
IPO DateJun 26, 2020
Beta1.43
52-Week Range$3.5 – $6.14
Avg Volume173,782
ExchangeNASDAQ
Websitepolypid.com
Ownership
Float61.2%
Shares Outstanding20.3M
Recent Insider Trades
Warshavsky OriAWARD
May 11, 202646,000 shares @ $4.46
Missulawin JonathanAWARD
May 11, 202649,000 shares @ $4.46
Hazan Dalit FellousAWARD
May 11, 202675,000 shares @ $4.46
Barenholz YechezkelAWARD
Jul 15, 20269,132 shares @ $4.46
Stein Robert BenjaminAWARD
Jul 15, 20269,132 shares @ $4.46
Peers
Recent News
PolyPid: Strong Phase 3 Data Support A Buy Ahead Of November's FDA Decision
Nov 4, 2026 · seekingalpha.com
PolyPid Ltd. (PYPD) Analyst/Investor Day Transcript
Oct 29, 2026 · seekingalpha.com
PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026
Oct 29, 2026 · globenewswire.com
PolyPid Targets 2027 D-PLEX100 Launch, Unveils Diabetic Foot Infection Program
Oct 29, 2026 · marketbeat.com
Data last updated: Nov 9, 2026, 04:30 AM